~~<i id='FFC0F24EAD'><strike id='FFC0F24EAD'><tt id='FFC0F24EAD'><pre id='FFC0F24EAD'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-08-12 18:46:42 Page View：616

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State of the Union pitch: Bigger Medicare drug price negotiations
Next article： Sports medicine is finally prioritizing gender equality

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Mike Pence clashes with Tucker Carlson in Iowa

3:09TuckerCarlson,left,andformerVicePresidentMikePenceGettyImagesFormerFoxNewshostTuckerCarlsonclash

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Florida health officials providing scant details on measles cases

WithfewdetailsavailableaboutmeaslescasesinFlorida,peopleconsidering vacationstothestatewhowanttoavoi